📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. (2021)

First Author: Sacramento CQ

Attributed to: New Branched Polymers Excipients and Emulsions for Enhanced Drug Delivery funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/jac/dkab072

PubMed Identifier: 33880524

Publication URI: http://europepmc.org/abstract/MED/33880524

Type: Journal Article/Review

Volume: 76

Parent Publication: The Journal of antimicrobial chemotherapy

Issue: 7

ISSN: 0305-7453